Bright Minds Biosciences Inc. (CSE:DRUG)

Bright Minds Biosciences Financials Overview

Financials in millions CAD. Fiscal year is October - September.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Operating Income Operating Income Growth	-39.18	-13.61	-2.63	-7.2	-14.73	-8.62
Net Income Net Income Growth	-24.51	-12.23	-2.8	-7.37	-14.96	-8.65
Earnings Per Share EPS Growth	-2.86	-1.78	-0.65	-1.98	-6.06	-4.82
EPS Growth	-	-	-	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cash & Investments Cash & Investments Growth	307.83	82.91	5.72	6.75	11.63	19.76
Total Debt Total Debt Growth	0.07	0.13	0.12	0.07	0.14	-
Net Cash (Debt) Net Cash Growth	307.76	82.78	5.6	6.67	11.49	19.76
Net Cash Growth	500.55%	1377.97%	-16.08%	-41.90%	-41.86%	2370.22%
Net Cash Per Share Net Cash Per Share Growth	35.79	12.04	1.30	1.79	4.65	11.01

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Operating Cash Flow Operating Cash Flow Growth	-24.67	-8.69	-1.85	-7.02	-13.59	-7.32
Free Cash Flow Free Cash Flow Growth	-24.67	-8.69	-1.85	-7.02	-13.59	-7.32
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Selected indicators aren't available for this stock.

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error